What's Happening?
Arcturus Therapeutics Holdings Inc., a San Diego-based mRNA medicines company, is set to present at the Canaccord Genuity 46th Annual Growth Conference in Boston. The company specializes in developing therapeutics for liver and respiratory rare diseases
using its proprietary LUNAR® lipid-mediated delivery and STARR® mRNA technology. Arcturus has developed KOSTAIVE®, the first self-amplifying mRNA COVID vaccine approved globally, and is involved in collaborations for pandemic flu and mRNA vaccine manufacturing. The company's pipeline includes RNA therapeutic candidates for conditions like cystic fibrosis and ornithine transcarbamylase deficiency.
Why It's Important?
Arcturus Therapeutics' participation in the conference highlights the growing interest and investment in mRNA technology, which has gained prominence due to its role in COVID-19 vaccine development. The company's innovations in mRNA therapeutics could lead to significant advancements in treating rare diseases, potentially transforming the landscape of personalized medicine. This presentation offers an opportunity for Arcturus to attract investors and partners, furthering its research and development efforts.
What's Next?
Arcturus Therapeutics will continue to advance its mRNA technology platforms and expand its pipeline of therapeutic candidates. The company's ongoing collaborations and joint ventures, such as those with CSL Seqirus and ARCALIS, are expected to enhance its capabilities in mRNA vaccine and therapeutic manufacturing. Future developments in Arcturus' research could lead to new treatment options for rare diseases and broader applications of mRNA technology.
